Potential role of E4orf1 protein in aging-associated impairment in glycemic control

Suhadinie Gamage, P (Hemachandra) Reddy, Nikhil V. Dhurandhar, Vijay Hegde

Research output: Contribution to journalArticle

Abstract

Aging constitutes a major risk factor for the development of type-2 diabetes (T2D) where glucose tolerance declines with age, resulting in a high prevalence of T2D and impaired glucose tolerance in the elderly population. Currently more than half of the 20 million U.S. adults with T2D are above the age of 60, and the largest increase in T2D prevalence is expected in the elderly. Obesity is a causative factor for T2D associated insulin resistance and hyperglycemia. Furthermore, the aging process is accelerated by hyperglycemia and effective treatment options are limited for the vulnerable aging population. One of the mechanisms contributing to aging associated hyperglycemia is resistance to insulin-mediated glucose disposal. Chronic hyperglycemia also accelerates aging by increasing pro-inflammatory milieu leading to impaired immune function. Although currently available anti-diabetic agents improve glycemic control, they have potential serious side effects in some cases. Therefore, additional and better drugs are urgently needed for treatment of insulin resistance and aging associated health risk factors. This review presents the novel use of a microbial protein, E4orf1 as a potential anti-diabetic agent, which functions independent of insulin and obesity, highlighting the role of unique sources for future drug development.

Original languageEnglish (US)
JournalJournal of Diabetes and its Complications
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Hyperglycemia
Insulin Resistance
Proteins
Obesity
Glucose
Glucose Intolerance
Vulnerable Populations
Pharmaceutical Preparations
Insulin
Health
Therapeutics
Population

Keywords

  • Ad36
  • Aging
  • E4orf1
  • Glucose intolerance
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Potential role of E4orf1 protein in aging-associated impairment in glycemic control. / Gamage, Suhadinie; Reddy, P (Hemachandra); Dhurandhar, Nikhil V.; Hegde, Vijay.

In: Journal of Diabetes and its Complications, 01.01.2018.

Research output: Contribution to journalArticle

Gamage, Suhadinie ; Reddy, P (Hemachandra) ; Dhurandhar, Nikhil V. ; Hegde, Vijay. / Potential role of E4orf1 protein in aging-associated impairment in glycemic control. In: Journal of Diabetes and its Complications. 2018.
@article{30703b2dd4ba406bb5786f6dad739026,
title = "Potential role of E4orf1 protein in aging-associated impairment in glycemic control",
abstract = "Aging constitutes a major risk factor for the development of type-2 diabetes (T2D) where glucose tolerance declines with age, resulting in a high prevalence of T2D and impaired glucose tolerance in the elderly population. Currently more than half of the 20 million U.S. adults with T2D are above the age of 60, and the largest increase in T2D prevalence is expected in the elderly. Obesity is a causative factor for T2D associated insulin resistance and hyperglycemia. Furthermore, the aging process is accelerated by hyperglycemia and effective treatment options are limited for the vulnerable aging population. One of the mechanisms contributing to aging associated hyperglycemia is resistance to insulin-mediated glucose disposal. Chronic hyperglycemia also accelerates aging by increasing pro-inflammatory milieu leading to impaired immune function. Although currently available anti-diabetic agents improve glycemic control, they have potential serious side effects in some cases. Therefore, additional and better drugs are urgently needed for treatment of insulin resistance and aging associated health risk factors. This review presents the novel use of a microbial protein, E4orf1 as a potential anti-diabetic agent, which functions independent of insulin and obesity, highlighting the role of unique sources for future drug development.",
keywords = "Ad36, Aging, E4orf1, Glucose intolerance, Obesity, Type 2 diabetes",
author = "Suhadinie Gamage and Reddy, {P (Hemachandra)} and Dhurandhar, {Nikhil V.} and Vijay Hegde",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jdiacomp.2018.11.006",
language = "English (US)",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Potential role of E4orf1 protein in aging-associated impairment in glycemic control

AU - Gamage, Suhadinie

AU - Reddy, P (Hemachandra)

AU - Dhurandhar, Nikhil V.

AU - Hegde, Vijay

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aging constitutes a major risk factor for the development of type-2 diabetes (T2D) where glucose tolerance declines with age, resulting in a high prevalence of T2D and impaired glucose tolerance in the elderly population. Currently more than half of the 20 million U.S. adults with T2D are above the age of 60, and the largest increase in T2D prevalence is expected in the elderly. Obesity is a causative factor for T2D associated insulin resistance and hyperglycemia. Furthermore, the aging process is accelerated by hyperglycemia and effective treatment options are limited for the vulnerable aging population. One of the mechanisms contributing to aging associated hyperglycemia is resistance to insulin-mediated glucose disposal. Chronic hyperglycemia also accelerates aging by increasing pro-inflammatory milieu leading to impaired immune function. Although currently available anti-diabetic agents improve glycemic control, they have potential serious side effects in some cases. Therefore, additional and better drugs are urgently needed for treatment of insulin resistance and aging associated health risk factors. This review presents the novel use of a microbial protein, E4orf1 as a potential anti-diabetic agent, which functions independent of insulin and obesity, highlighting the role of unique sources for future drug development.

AB - Aging constitutes a major risk factor for the development of type-2 diabetes (T2D) where glucose tolerance declines with age, resulting in a high prevalence of T2D and impaired glucose tolerance in the elderly population. Currently more than half of the 20 million U.S. adults with T2D are above the age of 60, and the largest increase in T2D prevalence is expected in the elderly. Obesity is a causative factor for T2D associated insulin resistance and hyperglycemia. Furthermore, the aging process is accelerated by hyperglycemia and effective treatment options are limited for the vulnerable aging population. One of the mechanisms contributing to aging associated hyperglycemia is resistance to insulin-mediated glucose disposal. Chronic hyperglycemia also accelerates aging by increasing pro-inflammatory milieu leading to impaired immune function. Although currently available anti-diabetic agents improve glycemic control, they have potential serious side effects in some cases. Therefore, additional and better drugs are urgently needed for treatment of insulin resistance and aging associated health risk factors. This review presents the novel use of a microbial protein, E4orf1 as a potential anti-diabetic agent, which functions independent of insulin and obesity, highlighting the role of unique sources for future drug development.

KW - Ad36

KW - Aging

KW - E4orf1

KW - Glucose intolerance

KW - Obesity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85058575052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058575052&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2018.11.006

DO - 10.1016/j.jdiacomp.2018.11.006

M3 - Article

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

ER -